Skip to Content

Obizur Approval History

FDA Approved: Yes (First approved October 23, 2014)
Brand name: Obizur
Generic name: antihemophilic factor (recombinant)
Company: Baxter International Inc.
Treatment for: Hemophilia A

Obizur (antihemophilic factor [recombinant]) is an antihemophilic factor indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.

Development History and FDA Approval Process for Obizur

DateArticle
Oct 24, 2014Approval FDA Approves Obizur [Antihemophilic Factor (Recombinant)] for Acquired Hemophilia A

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide